RT3 is a synthetic peptide analog studied in preclinical research for its activity as a triple agonist of the GLP-1, GIP, and glucagon receptors. In vitro and in vivo laboratory models have explored its potential effects on metabolic regulation, energy balance, and receptor-mediated signaling cascades. This compound is frequently utilized in research focused on peptide stability, receptor binding affinity, and pharmacokinetic modeling in controlled experimental settings.